Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in CombinationAna Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.Journal of Neuro-Oncology|February 6, 2016
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trialCarmen Balana, Ramon De Las Penas, Juan Manuel Sepúlveda, et al.Melanoma Research|March 10, 2016
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima studyEnrique Espinosa, Virtudes Soriano, Josep Malvehy, et al.Pigment Cell & Melanoma Research|May 27, 2023
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 21, 2025
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registryMaria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, et al.Neuro-Oncology|April 25, 2020
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)Carmen Balana, Maria Angeles Vaz, Juan Manuel Sepúlveda, et al.Nature Medicine|June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFRMiguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.Pageof 5